

## Curriculum Vitae Europass

### Informazioni personali

|                    |                                                             |
|--------------------|-------------------------------------------------------------|
| Cognome(i)/Nome(i) | <b>Gronchi Alessandro</b>                                   |
| Indirizzo(i)       | Istituto Nazionale Tumori, via G. Venezian 1, 20133, Milano |
| Telefono(i)        | +39 02 2390 3234                                            |
| Fax                | +39 02 2390 2404                                            |
| E-mail             | alessandro.gronchi@istitutotumori.mi.it                     |
| Cittadinanza       | italiana                                                    |
| Data di nascita    | 11.06.1968                                                  |
| Sesso              | Maschile                                                    |

### Esperienza professionale

|                                       |                                                                                                      |
|---------------------------------------|------------------------------------------------------------------------------------------------------|
| Date                                  | Dal luglio 2011 ad oggi                                                                              |
| Lavoro o posizione ricoperti          | <b>Dirigente medico I liv. responsabile Struttura Semplice Chirurgia dei Sarcomi</b>                 |
| Principali attività e responsabilità  | Coordinamento dell'attività chirurgica dei sarcomi delle parti molli e della chirurgia del peritoneo |
| Nome e indirizzo del datore di lavoro | <b>Istituto Nazionale Tumori</b> , via G. Venezian 1, 20133 <b>Milano</b>                            |
| Tipo di attività o settore            | Chirurgia Oncologica                                                                                 |
| Date                                  | Dall'ottobre 2006 al giugno 2011                                                                     |
| Lavoro o posizione ricoperti          | <b>Dirigente medico I liv. con incarico di alta professionalità per la Chirurgia dei Sarcomi</b>     |
| Principali attività e responsabilità  | Coordinamento dell'attività chirurgica dei sarcomi delle parti molli                                 |
| Nome e indirizzo del datore di lavoro | <b>Istituto Nazionale Tumori</b> , via G. Venezian 1, 20133 <b>Milano</b>                            |
| Tipo di attività o settore            | Chirurgia Oncologica                                                                                 |
| Date                                  | Dall'aprile 2001 all'ottobre 2006                                                                    |
| Lavoro o posizione ricoperti          | <b>Dirigente medico I liv., Responsabile Chirurgia dei Sarcomi</b>                                   |
| Principali attività e responsabilità  | Coordinamento dell'attività chirurgica dei sarcomi delle parti molli                                 |
| Nome e indirizzo del datore di lavoro | <b>Istituto Nazionale Tumori</b> , via G. Venezian 1, 20133 <b>Milano</b>                            |
| Tipo di attività o settore            | Chirurgia Oncologica                                                                                 |
| Date                                  | Dal novembre 1999 ad aprile 2001                                                                     |
| Lavoro o posizione ricoperti          | <b>Dirigente medico I liv.</b>                                                                       |
| Principali attività e responsabilità  | Posizione a tempo pieno di Chirurgo Oncologo                                                         |
| Nome e indirizzo del datore di lavoro | Istituto Nazionale Tumori, via G. Venezian 1, 20133 Milano                                           |
| Tipo di attività o settore            | Chirurgia Oncologica                                                                                 |
| Date                                  | Dal luglio 1996 all'ottobre 1999                                                                     |
| Lavoro o posizione ricoperti          | Frequentatore / borsista / ricercatore associato / dirigente medico supplente                        |
| Principali attività e responsabilità  | Chirurgo oncologo                                                                                    |
| Nome e indirizzo del datore di lavoro | <b>Istituto Nazionale Tumori</b> , via G. Venezian 1, 20133 <b>Milano</b>                            |
| Tipo di attività o settore            | Chirurgia Oncologica                                                                                 |

|                                       |                                                |
|---------------------------------------|------------------------------------------------|
| Date                                  | Dal luglio 1994 al giugno 1996                 |
| Lavoro o posizione ricoperti          | Assistente a tempo pieno                       |
| Principali attività e responsabilità  | Chirurgo generale                              |
| Nome e indirizzo del datore di lavoro | St. Mary's Hospital Lacor – Gulu - Uganda      |
| Tipo di attività o settore            | Chirurgia generale e Ginecologia ed ostetricia |

## Istruzione e formazione

|                                                                      |                                                                                |
|----------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Date                                                                 | Dal 1992 al 1997                                                               |
| Titolo della qualifica rilasciata                                    | <b>Specializzazione in Chirurgia generale ad indirizzo chirurgia d'urgenza</b> |
| Principali tematiche/competenza professionali possedute              | Chirurgia generale                                                             |
| Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione | Università di Milano                                                           |
| Livello nella classificazione nazionale o internazionale             | ISCED 5A (Field of Education: 72)                                              |
| Date                                                                 | 1993                                                                           |
| Titolo della qualifica rilasciata                                    | <b>Abilitazione all'esercizio della professione di Medico chirurgo</b>         |
| Principali tematiche/competenza professionali possedute              | Medicina e Chirurgia                                                           |
| Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione | Università di Milano                                                           |
| Date                                                                 | Dal 1986 al 1992                                                               |
| Titolo della qualifica rilasciata                                    | <b>Laurea in Medicina e chirurgia</b> (con lode)                               |
| Principali tematiche/competenza professionali possedute              | Medicina e Chirurgia                                                           |
| Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione | Università di Milano                                                           |
| Livello nella classificazione nazionale o internazionale             | ISCED 5A (Field of Education: 72)                                              |

## Capacità e competenze personali

Madrelingua(e) **Italiano**

Altra(e) lingua(e)

Autovalutazione

Livello europeo (\*)

**Inglese**

| Comprensione |                  |         |                  | Parlato           |                  |                  |                  | Scritto |                  |
|--------------|------------------|---------|------------------|-------------------|------------------|------------------|------------------|---------|------------------|
| Ascolto      |                  | Lettura |                  | Interazione orale |                  | Produzione orale |                  |         |                  |
| C1           | Livello avanzato | C1      | Livello avanzato | C1                | Livello avanzato | C1               | Livello avanzato | C1      | Livello avanzato |

(\*) Quadro comune europeo di riferimento per le lingue

## Ulteriori informazioni

- Membro della Sarcoma Task Force della European Society for Medical Oncology (ESMO)
- Membro del consiglio direttivo della Connective Tissue Oncology Society (CTOS) 2009-2012, tesoriere nel 2013, segretario nel 2014, vice presidente nel 2015, presidente nel 2016
- Membro del consiglio direttivo dell'Italian Sarcoma Group (ISG)
- Membro del consiglio direttivo della Società Italiana di Chirurgia Oncologica (SICO)
- Chair del Soft Tissue and Bone Sarcoma Group dell'EORTC
- Membro dell' International Committee della Society of Surgical Oncology (SSO) 2009-2011
- Associate Editor di Sarcoma Journal
- Associate Editor of Clinical Sarcoma Research
- Section Editor per i Sarcomi degli Annals of Surgical Oncology 2009-2014
- Membro delle seguenti società professionali/scientifiche:
  - European Society for Medical Oncology (ESMO)
  - European Muscolo-Skeletal Oncology Society (EMSOS)
  - Society of Surgical Oncology (SSO)
  - American Society of Clinical Oncology (ASCO)
  - Connective Tissue Oncology Society (CTOS)
  - Società Europea di Chirurgia Oncologica (ESSO)
  - Società Italiana di Chirurgia Oncologica (SICO)
  - Società Italiana di Chirurgia (SIC)

**Pubblicazioni:** v. Allegati 1-2-3-4

**Esperienza in trial clinici:** v. Allegato 5

## Allegati

- Allegato 1: Elenco delle **Pubblicazioni censite da Meline, in inglese**
- Allegato 2: Elenco delle **Pubblicazioni non censite da Meline, in inglese**
- Allegato 3: Elenco dei **Capitoli di libri, in inglese**
- Allegato 4: Elenco dei **Libri, in italiano**
- Allegato 5: Elenco **Trial Clinici condotti**



## Allegato 1

### Elenco delle pubblicazioni censite da Meline, in inglese

1. Bozzetti F., Bertario L., Rossetti C., Gennari L., Andreola S., Baratti D., **Gronchi A.** Surgical treatment of locally recurrent rectal carcinoma. *Disease of the Colon Rectum* 1997; 40 (12): 1421-1424.
2. Bozzetti F., Baratti D., Andreola S., Zucali R., Schiavo M., Spinelli P., **Gronchi A.**, Valvo F., Mariani L., Gennari L. Preoperative Radiation Therapy for T2-T3 cancers of the middle-to-lower rectum. *Cancer* 1999; 86 (3): 398-404.
3. Azzarelli A., **Gronchi A.**, Bertulli R., Tesoro Tess J.D., Baratti D., Pennacchioli E., Dileo P., Rasponi A., Pilotti S., Casali P.G. Low-dose chemotherapy with Methotrexate and Vinblastine for advanced aggressive fibromatosis. *Cancer* 2001, 92 (5): 1259-1264.
4. Mezzelani A., Mariani L., Tamborini E., Agus V., Riva C., Lo Vullo S., Fabbri A., Stumbo M., Azzarelli A., Casali P.G., **Gronchi A.**, Sozzi G., Pierotti M.A., Pilotti S. SYT-SSX fusion genes and prognosis in synovial sarcoma. *Br J of Cancer* 2001, 85 (10): 1535-9.
5. Ferrari A., Casanova M., Bisogno G., Mattke A., Meazza C., **Gronchi A.**, Cecchetto G., Fidani P., Kunz D., Treuner J., Carli M. Hemangiopericytoma in pediatric age: a report from the italian and german soft tissue sarcoma cooperative group. *Cancer* 2001, 92 (10): 2692-2698.
6. Tamborini E., Agus V., Perrone F., Papini D., Romanò R., Pasini B., **Gronchi A.**, Colecchia M., Rosai J., Pierotti M.A., Pilotti S. Lack of SYT-SSX fusion transcripts in malignant peripheral nerve sheath tumors on RT-PCR analysis of 38 archival cases. *Lab Invest.* 2002, 82 (5): 609-618.
7. Deraco M, **Gronchi A.**, Mazzaferro V, Inglese MG, Pennacchioli E, Kusamura S, Rizzi M, Anselmi RA Jr, Vaglini M. Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei. *Tumori.* 2002, 88(5):370-5.
8. **Gronchi A.**, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, Bertulli R, Fiore M, Olmi P, Santinami M, Rosai J. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. *J Clin Oncol.* 2003; 21(7):1390-7.
9. Baratti D, **Gronchi A.**, Pennacchioli E, Lozza L, Colecchia M, Fiore M, Santinami M. Chordoma: natural history and results in 28 patients treated at a single institution. *Ann Surg Oncol.* 2003; 10(3):291-6.
10. Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, Navarria P, Collini P, **Gronchi A.**, Olmi P, Fossati-Bellani F, Casali PG. Rhabdomyosarcoma in adults: a retrospective analysis of 171 patients treated at a single institution. *Cancer* 2003; 98 (3): 571-580.
11. Collini P, Mezzelani A, Modena P, Dagrada P, Tamborini E, Luksch R, **Gronchi A.**, Navarria P, Sozzi G, Pilotti S. Evidence of neural differentiation in a case of post-therapy primitive neuroectodermal tumor/Ewing sarcoma of bone. *Am J Surg Pathol* 2003 Aug;27(8):1161-1166.
12. Deraco M, Kusamura S, **Gronchi A.** [Cytoreductive surgery (peritonectomy) and intraperitoneal hyperthermic chemotherapy: an innovative and effective approach to the treatment of pseudomyxoma peritonei]. *Tumori.* 2003 89(4 Suppl): 54-5.
13. Perrone F, Tabano S, Colombo F, Dagrada G, Birindelli S, **Gronchi A.**, Colecchia M, Pierotti MA and Pilotti S. p15INK4b, p14ARF and p16INK4a inactivation in sporadic and NF1-related Malignant Peripheral Nerve Sheath Tumors. *Clin Cancer Res.* 2003 Sept.; 9(11): 4132-4138.
14. Tamborini E, Bonadiman L, Greco A, **Gronchi A.**, Riva C, Bertulli R, Casali PG, Pierotti MA and Pilotti S. Alternative expression of ligand-activated kit and PDGFRbeta tyrosine kinase receptors in synovial sarcoma. *Clin Cancer Res* 2004 Feb; 10(3): 938-943.
15. **Gronchi A.**, Diment J, Colecchia M, Fiore M and Santinami M. Atypical pleomorphic epithelioid angiomyolipoma localized to the pelvis: a case report and review of the literature. *Histopathology* 2004 Mar; 44(3): 292-295.
16. Rossi CR, Deraco M, De Simone M, Mocellin S, Pilati P, Foletto M, Cavaliere F, Kusamura S, **Gronchi A.**, Lise M. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis. *Cancer* 2004 May 1;100(9):1943-50.
17. **Gronchi A.**, Casali PG, Fiore M, Mariani L, Lo Vullo S, Bertulli R, Colecchia M, Lozza L, Olmi P, Santinami M and Rosai J. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. *Cancer* 2004, 100(11): 2448-2455.
18. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, **Gronchi A.**, Bertulli R, Colecchia M, Casali PG, Pierotti M and Pilotti S. A new mutation in the ATP pocket of Kit receptor is responsible for acquired resistance to Imatinib in a patient with gastrointestinal stromal tumor (GIST). *Gastroenterology* 2004, 127(1):294-9.
19. Ferrari A, **Gronchi A.**, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, Casali PG. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. *Cancer* 2004, 101(3): 627-634.
20. Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, **Gronchi A.**, Orlandi R, Ripamonti C, Spreafico C, Alberti D, Bertieri R, Bertulli R, Coco P, Colecchia M, Fumagalli E, Greco A, Grosso F, Negri T, Olmi P, Pierotti MA, Pilotti S. Imatinib mesylate in chordoma. *Cancer* 2004, 101(9):2086-97.
21. Kusamura S, Raspagliesi F, Baratti D, **Gronchi A.**, Casali P, Deraco M. Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: a feasibility study. *J Chemother.* 2004, 16 Suppl 5:19-22.



22. Mariani L, Miceli R, Kattan MW, Brennan MF, Colecchia M, Fiore M, Casali PG and **Gronchi A**. Validation and adaptation of a nomogram for predicting survival of extremity soft tissue sarcoma using a three grade system. *Cancer* 2005, 103(2):402-408.
23. **Gronchi A**, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, Bertulli R, Collini P, Lozza L, Olmi P and Rosai J. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: A series of 911 consecutive patients treated at a single institution. *J Clin Oncol* 2005, 23(1):96-104.
24. Diment J, Tamborini E, Casali PG, **Gronchi A**, Carney JA and Colecchia M. Carney Triad: case report and molecular analysis of gastric tumor. *Human Pathol* 2005, 36: 112-116.
25. Ferrari A, Casanova M, Collini P, Meazza C, Lukcsch R, Massimino M, Cefalo G, Terenziani M, Spreafico F, Catania S, Gandola L, **Gronchi A**, Mariani L and Fossati-Bellani F. Adult-type soft tissue sarcoma in pediatric age: experience at the Istituto Nazionale Tumori in Milan. *J Clin Oncol*. 2005, 23(18): 4021-4030.
26. Blay JY, Bonvalot S, Casali PG, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, **Gronchi A**, Hogendoorn PCW, Joensuu H, Le Cesne A, Joan Mac Clure, Joan Maurel, Nina Nupponen, Isabelle Ray-Coquard, Peter Reichardt, Raf Sciort, Sigrid Stroobants, Martine van Glabbeke, Allan van Oosterom, Georges D Dimetri. A consensus meeting for the management of gastro-intestinal stromal tumors. Report from the ESMO GIST consensus conference of March 20-21st, 2004. *Ann Oncol*. 2005 Apr;16(4):566-78.
27. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V, Lagonigro MS, Gabanti E, Caramuta S, Greco A, Torre GD, **Gronchi A**, Pierotti MA, Pilotti S. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. *Cancer*. 2005, 104: 159-169.
28. Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, Collini P, Olmi P, Casali PG and **Gronchi A**. Dermatofibrosarcoma Protuberans treated at a single institution: a surgical disease with a high cure rate. *J Clin Oncol*. 2005; 23:7669-75.
29. Casanova M, Ferrari A, Collini P, Bisogno G, Aleggioro R, Cecchetto G, **Gronchi A**, Meazza C, Garaventa A, Di Cataldo A, Carli M. Epithelioid Sarcoma in children and adolescents: a report from the Italian soft tissue sarcoma committee. *Cancer*. 2006; 106(3):708-17.
30. Fiore M, Casali PG, Miceli R, Mariani L, Bertulli R, Lozza L, Collini P, Olmi P, Mussi C and **Gronchi A**. Prognostic effect of re-excision in adult soft tissue sarcoma of the extremities. *Ann Surg Oncol*. 2006; 13(1):110-7.
31. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S and **Gronchi A**. Malignant peripheral nerve sheath tumours: prognostic factors and survival in a series of patients treated at a single institution. *Cancer*. 2006; 107(5):1065-1074.
32. Tamborini E, Priol S, Negri T, Lagonigro MS, Miselli F, Greco A, **Gronchi A**, Casali PG, Ferrone M, Fermeleglia M, Carbone A, Pierotti MA, Pilotti S. Functional analyses and molecular modeling of two c-Kit mutations responsible for Imatinib secondary resistance in GIST patients. *Oncogene*. 2006, 25(45): 6140-6146.
33. Costa A, Daidone MG, Daprao L, Villa R, Cantù S, Pilotti S, Mariani L, **Gronchi A**, Henson JD, Reddel RR and Zaffaroni N. Telomere maintenance mechanisms in liposarcoma: association with histologic subtypes and disease progression. *Cancer Res*. 2006; 66(17):8918-24.
34. Tamborini E, Miselli F, Negri T, Lagonigro S, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, **Gronchi A**, Perrone F, Carbone A, Pierotti MA, Casali PG and Pilotti S. Molecular and biochemical analyses of PDGFRB, PDGFRA and KIT receptors in chordoma. *Clin Cancer Res*. 2006; 12(23):6920-8.
35. Pennacchioli E, Deraco M, Mariani L, Fiore M, Mussi C, Collini P, Olmi P, Casali PG, Santinami M and **Gronchi A**. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. *Ann Surg Oncol* 2007; 14(2): 553-9.
36. **Gronchi A**, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S and Casali PG. Surgery of residual disease following molecular targeted therapy with Imatinib mesylate in advanced/metastatic GIST. *Ann Surg* 2007; 245: 341-346.
37. Miselli F, Casieri P, Negri T, Orsenigo M, Lagonigro MS, **Gronchi A**, Fiore M, Casali PG, Bertulli R, Carbone A, Pienotti MA, Tamborini E and Pilotti S. c-Kit/PDGFR gene status alterations possibly related to primary Imatinib resistance in Gastrointestinal Stromal Tumors. *Clin Cancer Res* 2007; 13(8): 2369-77.
38. Tamborini E, Casieri P, Miselli F, Orsenigo M, Negri T, Piacenza C, Stacchiotti S, **Gronchi A**, Pastorino U, Pierotti MA and Pilotti S. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. *J Pathol* 2007; 212(2):227-235.
39. **Gronchi A**, Miceli R, Fiore M, Collini P, Lozza L, Grosso F, Mariani L and Casali PG. Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. *Ann Surg Oncol* 2007; 14(5):1583-90.
40. Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, Collini P, Lozza L, Mariani L, Casali PG and **Gronchi A**. Myxoid/round cell and pleomorphic liposarcoma: prognostic factors and survival in a series of patients treated at a single institution. *Cancer* 109: 2522-2531; 2007.
41. Casali PG, Stacchiotti S, Sangalli C, Olmi P, **Gronchi A**. Chordoma. *Curr Opin Oncol* 2007; 19(4): 367-370.
42. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero TC, Jimeno J, D'Incalci M, **Gronchi A**, Fletcher JA, Pilotti S, Casali PG. Efficacy of trabectedin (ET-743) in advanced pre-treated myxoid liposarcomas. *Lancet Oncol* 2007; 8(7): 595-602.



43. Casanova M, Meazza C, **Gronchi A**, Fiore M, Zaffignani E, Podda M, Collini P, Gandola L, Ferrari A. Soft tissue sarcoma of the extremities in patients of pediatric age. *J Child Orthop* 2007; 1(3):195-203.
44. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, **Gronchi A**, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J; NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. *J Natl Compr Canc Netw*. 2007; 5 Suppl 2:S1-29.
45. **Gronchi A**, Olmi P and Casali PG. Combined modalities approach for localized adult extremity soft tissue sarcoma. *Expert Rev. Anticancer Ther* 2007; 7(8): 1135-1144.
46. Signoroni S, Frattini M, Negri T, Pastore E, Tamborini E, Casieri P, Orsenigo M, Da Riva L, Radice P, Sala P, **Gronchi A**, Bertario L, Pierotti MA and Pilotti S. Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as potential targets in treating Aggressive Fibromatosis. *Clin Cancer Res* 2007; 13(17): 5034-5040.
47. Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, Olmi P, Collini P, Redaelli S, Fiore M and **Gronchi A**. Epithelioid Sarcoma: Prognostic Factors and Survival in a series of Patients Treated at a Single Institution. *Ann Surg Oncol* 2007; 14(12):3542-51.
48. Ferrari A, Miceli R, Casanova M, **Gronchi A**, Collini P, Meazza C, Zaffignani E, Massimino M, Spreafico F, Mariani L. Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma. *Eur J Cancer*. 2007 43(18): 2691-2697.
49. Venturini L, Erdas R, Costa A, **Gronchi A**, Pilotti S, Zaffaroni N and Daidone MG APB detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcoma. *J Pathol* 2008; 214(4): 410-414.
50. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2008 May;19 Suppl 2:ii35-8.
51. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY; ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2008 May;19 Suppl 2:ii89-93.
52. Fiore M, Locati P, Mussi C, Guarino A, Piva L, Santinami M and **Gronchi A**. Banked venous homograft replacement of the inferior vena cava for primary leiomyosarcoma. *Eur J Surg Oncol* 2008; 34(6): 720-724.
53. Mussi C, Schildhaus HU, **Gronchi A**, Wardelmann E and Hohenberger P. Therapeutic Consequences From Molecular Biology For GIST Patients Affected By Neurofibromatosis Type 1. *Clin Cancer Res* 2008; 14(14): 4550-4555.
54. Mussi C, Collini P, Miceli R, Barisella M, Mariani L, Fiore M, Casali PG and **Gronchi A**. Prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of patients surgically treated at a single institution. *Cancer* 2008; 113: 1657-1665.
55. Miselli F, Negri T, **Gronchi A**, Losa M, Conca E, Brich S, Fumagalli E, Fiore M, Casali PG, Pierotti MA, Tamborini E, Pilotti S. Is autophagy rather than apoptosis the regression driver in Imatinib-treated gastrointestinal stromal tumours ? *Transl Oncol* 2008; 1(4): 177-186.
56. Negri T, Bozzi F, Conca E, Brich S, **Gronchi A**, Bertulli R, Fumagalli E, Pierotti MA, Tamborini E, Pilotti S. Oncogenic and ligand-dependent activation of KIT/PDGFRα in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). *J Pathol* 2009; 217:103-112
57. **Gronchi A**, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E, Mariani L and Casali PG. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. *J Clin Oncol* 2009; 27(1): 24-30.
58. Ferrari A, Miceli R, Casanova M, Meazza C, Zaffignani E, **Gronchi A**, Piva L, Collini P, Podda M, Massimino M, Luksch R, Cefalo G, Terenziani M, Spreafico F, Polastra D, Mariani L. Soft Tissue Sarcoma of childhood and adolescence: the prognostic role of tumor size changes in relation to the patient's body size. *J Clin Oncol* 2009; 27(3): 371-376..
59. Stacchiotti S, Tamborini E, Marrari A, Brich S, Arisi Rota S, Orsenigo M, Crippa F, Morosi C, **Gronchi A**, Pierotti MA, Casali PG and Pilotti S. Response to sunitinib malate in advanced alveolar soft part sarcoma (ASPS). *Clin Cancer Res* 2009, 15(3): 1096-1104
60. Pennacchioli E, Fiore M and **Gronchi A**. Hyperthermia as an adjunctive treatment for soft tissue sarcoma. *Expert Rev. Anticancer Ther* 2009, 9(2): 199-210
61. Forni C, Minuzzo M, Viridis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, **Gronchi A**, Aman P, Casali PG, D'Incalci M, Pilotti S and Mantovani R. Trabectedin (ET-743) promotes differentiation of myxoid liposarcoma tumors. *Mol Cancer Ther* 2009, 8(2): 449-457
62. **Gronchi A**, Bonvalot S, Le Cesne A and Casali PG. Resection of uninvolved adjacent organs can be part of surgery for retroperitoneal soft tissue sarcoma. *J Clin Oncol* 2009, 27(12):2106-2107
63. **Gronchi A**, Judson I, Nishida T, Poveda A, Martin J, Reichardt P, Casali PG, Le Cesne A, Hohenberger P, Blay JY. Adjuvant treatment with Imatinib for GIST: solid ground or still quicksand ? A comment on behalf of the EORTC soft tissue and bone sarcoma group, the Italian sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group, the Spanish Sarcoma Group (GEIS). *Eur J Cancer* 2009, 45(7):1103-1106.
64. Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, Piovesan C, Dileo P, Torri V, **Gronchi A** and Casali PG Tumor response assessment in high grade soft tissue sarcomas (STS): a pilot study to assess the correlation between radiological and pathological response using both RECIST and Choi's criteria. *Radiology* 2009, 251(2): 447-456



65. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG and **Gronchi A**. Preoperative Imatinib mesylate for unresectable or locally advanced primary Gastrointestinal Stromal Tumors (GIST). *Eur J Surg Oncol* 2009; 35: 739-745.
66. Thomas DM, O'Sullivan B and **Gronchi A**. Current concepts and future perspectives in Retroperitoneal Soft Tissue Sarcoma management. *Expert Rev Anticancer Ther* 2009; 9(8):1145-57
67. Reichardt P, Hogendoorn PC, Tamborini E, Loda M, **Gronchi A**, Poveda A, Schöffski P. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. *Semin Oncol.* 2009; 36(4):290-301.
68. Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Pécoux C, Casali PG, Le Cesne A, **Gronchi A** and Bonvalot S. Desmoid-Type Fibromatosis: a front-line conservative approach to select patients for surgical treatment. *Ann Surg Oncol* 2009; 16(9): 2587-2593.
69. Grosso F, Sanfilippo R, Virdis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D'Incalci M, **Gronchi A**, Pilotti S and Casali PG. Trabectedin in Myxoid Liposarcomas (MLS): a long-term analysis of a single institution series. *Ann Oncol* 2009; 20(8):1439-44
70. Colombo C and **Gronchi A**. Desmoid-type fibromatosis: what works best? *Eur J Cancer* 2009; 45 suppl1: 466-467.
71. Conca E, Negri T, **Gronchi A**, Fumagalli E, Tamborini E, Pavan GM, Fermeglia M, Pierotti MA, Priol S and Pilotti S. Activate and Resist: L576P in GIST. *Mol Cancer Ther* 2009; 8(9):2491-2495
72. Stacchiotti S, Marrari A, Tamborini E, Palassini E, Virdis E, Messina A, Crippa F, Morosi C, **Gronchi A**, Pilotti S and Casali PG. Response to imatinib plus sirolimus in advanced chordoma. *Ann Oncol* 2009; 20(11):1886-1894.
73. Perrone F, Da Riva L, Orsenigo M, Losa M, Jocolle G, Millefanti C, Pastore E, **Gronchi A**, Pierotti MA, and Pilotti S. PDGFRA, PDGFRB, EGFR and downstream signalling activation in malignant peripheral nerve sheath tumour. *Neuro Oncology* 2009; 11(6): 725-736
74. Stacchiotti S, Casali PG, Lo Vullo S, Mariani L, Palassini E, Mercuri M, Alberghini M, Pilotti S, Zanella L, **Gronchi A** and Picci P. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centres. *Ann Surg Oncol* 2010; 17: 211-219
75. Meazza C, Bisogno G, **Gronchi A**, Fiore M, Cecchetto G, Alaggio R, Milano GM, Casanova M, Carli M, Ferrari A. Aggressive fibromatosis in children and adolescents: the italian experience. *Cancer* 2010; 116(1):233-240
76. Mussi C, Ronellenfisch U, Jakob J, Tamborini E, Reichardt P, Casali PG, Fiore M, Hohenberger P and **Gronchi A**. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients ? *Ann Oncol* 2010; 21(2):403-408
77. **Gronchi A**, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, Fiore M and Casali PG. Extremity soft tissue sarcoma in a series of patients treated at a single institution: the local control directly impacts survival. *Ann Surg* 2010; 251: 512-517
78. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, **Gronchi A**, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M and Allavena P. Anti-tumor and anti-inflammatory effects of Trabectedin on human myxoid liposarcoma cells. *Cancer Res* 2010; 70(6): 2235-2244
79. **Gronchi A**, Blay JY and Trent JC. The Role of High-Dose Imatinib in the Management of Patients with Gastrointestinal Stromal Tumor (GIST). *Cancer* 2010; 116(8):1847-1858
80. Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, **Gronchi A** and Casali PG. Tumor response to Sunitinib Malate observed in Clear Cell Sarcoma. *Ann Oncol* 2010; 21(5):1130-1131
81. Ardoino I., Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, Collini P, Stacchiotti S, Casali PG and **Gronchi A**. Histology-Specific Nomogram for Primary Retroperitoneal Sarcoma. *Cancer* 2010; 116: 2429-2436
82. Stacchiotti S, Negri T, Palassini E, Conca E, **Gronchi A**, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG and Pilotti S. Sunitinib malate and Figitumumab in solitary fibrous tumor (SFT): patterns and molecular bases of tumor response. *Mol Cancer Ther* 2010; 9(5): 1286-1297
83. Bonvalot S, Miceli R, Berselli M, Causeret S, Colombo C, Mariani L, Bouzaïene H, Le Pécoux C, Casali PG, Le Cesne A, Fiore M and **Gronchi A**. Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma carried out at high volume centers is safe and associated to an improved local control. *Ann Surg Oncol* 2010; 17: 1507-1514
84. Venturini L, Motta R, **Gronchi A**, Daidone MG and Zaffaroni N. Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. *BMC Cancer* 2010; 10: 254
85. Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET. Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2010; 21 Suppl 5:v198-203
86. Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2010; 21 Suppl 5:v98-102.
87. Hogendoorn PC; ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Hogendoorn PC, Jurgens H, Paulussen M, Rozeman L, Taminiau AH, Whelan J, Vanel D. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2010; 21 Suppl 5:v204-13.
88. Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S, Conca E, **Gronchi A**, Stacchiotti S, Manenti G, Casali PG, Pierotti MA and Pilotti S. Analysis of Receptor Tyrosine Kinases (RTK) and Downstream Pathways in Chordomas. *Neuro Oncol* 2010; 12(8): 776-789



89. Frapolli R, Tamborini E, Virdis E, Bello E, Tarantino E, Marchini S, Grosso F, Sanfilippo R, **Gronchi A**, Tercero J, Peloso G, Casali PG, Pilotti S, D'Incalci M. Novel models of Myxoid Liposarcoma Xenografts mimicking the biological and pharmacological features of human tumors. *Clin Cancer Res* 2010;16(20):4958-4967
90. Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, Casali PG and **Gronchi A**. Alveolar Soft Part Sarcoma: clinical presentation, treatment and outcome in a series of 33 patients at a single institution. *Ann Surg Oncol* 2010; 17: 3229-3233
91. Gatta G, Capocaccia R, Trama A, Martinez-Garzia C; RARECARE Working Group. The burden of rare cancers in Europe. *Adv Exp Med Biol* 2010; 686: 285-303
92. Baratti D, Pennacchioli E, Kusamura S, Fiore M, Balestra MR, Colombo C, Mingrone E, **Gronchi A** and Deraco M. Peritoneal Sarcomatosis: is there a subset of patients who may benefit of a cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? *Ann Surg Oncol* 2010; 17(12): 3220-3228
93. Orsenigo M, Brich S, Riva C, Conca E, Bertulli R, Dileo P, **Gronchi A**, Casali PG, Pierotti MA, Tamborini E, Pilotti S. Fluorescence in situ hybridization analysis and immunophenotyping of c-kit/PDGFRα and Bcl-2 expression in gastrointestinal stromal tumors. *Anal Quant Cytol Histol* 2010; 32(4): 225-233
94. Gennaro M, Valeri B, Casalini P, Carcangiu ML, **Gronchi A**, Conti AR, Agresti R, Greco M. Angiosarcoma of the breast and vascular endothelial growth factor receptor. *Tumori*. 2010; 96(6):930-935.
95. Dileo P, Priol S, Tamborini E, Negri T, Stacchiotti S, **Gronchi A**, Posocco P, Laurini E, Coco P, Fumagalli E, Casali PG, Pilotti S. Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRα mutations: an imaging, biochemical and molecular modeling study. *Int J Cancer* 2011; 128(4): 983-990
96. Gasparini P, Facchinetti F, Boeri M, Lorenzetto E, Livio A, **Gronchi A**, Ferrari A, Massimino M, Spreafico F, Giangaspero F, Forni M, Maestro R, Alaggio R, Pilotti S, Collini P, Modena P and Sozzi G. Prognostic determinants in Epithelioid Sarcoma. *Eur J Cancer* 2011; 47: 287-295
97. Bonvalot S and **Gronchi A**. ILP and RT: the study that will never be. *Ann Surg Oncol* 2011; 18: 303-305
98. Sanfilippo R, Miceli R, Grosso F, Fiore M, Pennacchioli E, Puma E, Barisella M, Sangalli C, Mariani L, Casali PG and **Gronchi A**. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. *Ann Surg Oncol* 2011; 18: 720-725
99. Berselli M, Coppola S, Colombo C, Pennacchioli E, Fiore M and **Gronchi A**. Morbidity of Left Pancreatectomy when associated with multivisceral resection for Abdominal Mesenchymal Neoplasm. *JOP* 2011; 12(2): 138-144
100. **Gronchi A**, Miceli R, Colombo C, Collini P, Stacchiotti S, Olmi P, Mariani L, Bertulli R, Fiore M and Casali PG. Primary Extremity Soft Tissue Sarcoma: outcome improvement over time at a single institution. *Ann Oncol* 2011; 22(7): 1675-1681
101. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, **Gronchi A**, Casali PG and Pilotti S. Sunitinib in advanced alveolar soft part sarcoma: evidence of direct antitumor effect. *Ann Oncol* 2011; 22(7): 1682-1690
102. Bozzi F, Conca E, Manenti G, Negri T, Brich S, **Gronchi A**, Pierotti MA, Tamborini E, Pilotti S. High CD133 expression levels in gastrointestinal stromal tumors. *Cytometry B Clin Cytom* 2011; 80(B): 238-247
103. **Gronchi A** and Pollock RE. Surgery in retroperitoneal soft tissue sarcoma: a call for a consensus between Europe and North America. *Ann Surg Oncol* 2011; 18: 2107-2110
104. Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, **Gronchi A**, Pilotti S and Casali PG. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. *Int J Cancer* 2011; 129(7): 1761-1772
105. Rossi S, Miceli R, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Toffolatti L, Laurino L, Mariani L, Vinaccia V, Gnocchi C, **Gronchi A**, Casali PG and Dei Tos AP. Natural history of Imatinib-naïve GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. *Am J Surg Pathol* 2011; 35(11):1646-1656
106. Da Riva L, Bozzi F, Mondellini P, Micciché F, Fumagalli E, Vaghi E, Tarantino E, Huber V, **Gronchi A**, Tamborini E, Pierotti MA, Pilotti S and Bongarzone I. Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy. *J Transl Med* 2011; 9:158
107. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer*. 2011; 47(17): 2493-2511
108. Visser O, Adolfsson J, Rossi S, et al. Incidence and survival of rare urogenital cancers in Europe. *Eur J Cancer*. 2012; 48(4):456-464
109. Van Dijk BA, Gatta G, Capocaccia R, et al. Rare cancers of the head and neck area in Europe. *Eur J Cancer*. 2012; 48(6):783-796.
110. Mallone S, De Vries E, Guzzo M, et al. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. *Eur J Cancer*. 2012; 48(8):1167-1175
111. Negri T, Brich S, Conca E, Bozzi F, Orsenigo M, Stacchiotti S, Alberghini M, Mauro V, **Gronchi A**, Dusio GF, Pelosi G, Picci P, Casali PG, Pierotti MA, Pilotti S. Receptor Tyrosine Kinase Pathway Analysis Sheds Light on Similarities between Clear Cell Sarcoma and Metastatic Melanoma. *Gene Chromosomes Cancer* 2012; 51(2): 111-126



112. Fiore M, Colombo C, Locati P, Berselli M, Radaelli S, Morosi C, Casali PG and **Gronchi A**. Surgical technique, morbidity and outcome of primary retroperitoneal sarcoma involving inferior vena cava. *Ann Surg Oncol* 2012; 19(2): 511-518.
113. Trama A, Mallone S, Nicolai N, Necchi A, Schaapveld M, Gietema J, Znaor A, Ardanaz E, Berrino F; RARECARE Working Group. Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. *Eur J Cancer*. 2012; 48(2):159-169
114. Faivre J, Trama A, De Angelis R, Elferink M, Siesling S, Audisio R, Bosset JF, Cervantes A, Lepage C; RARECARE Working Group. Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002. *Eur J Cancer*. 2012; 48(10):1417-24
115. Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, Weber DC, Ricardi U, Slowinski J, Brandes A; RARECARE working group. Epidemiology of glial and non-glial brain tumours in Europe. *Eur J Cancer*. 2012; 48(10):1532-42
116. Gatta G, Ferrari A, Stiller CA, Pastore G, Bisogno G, Trama A, Capocaccia R; RARECARE Working Group. Embryonal cancers in Europe. *Eur J Cancer*. 2012; 48(10):1425-33
117. van der Zwan JM, Mallone S, van Dijk B, Bielska-Lasota M, Otter R, Foschi R, Baudin E, Links TP; RARECARE WG. Carcinoma of endocrine organs: results of the RARECARE project. *Eur J Cancer*. 2012;48(13):1923-31
118. **Gronchi A**, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, Hohl RJ, Demetri GD, Le Cesne A, Lardelli P, Perez I, Nieto A, Tercero JC, Alfaro V, Tamborini E and Blay JY. Phase II Clinical Trial of Neoadjuvant Trabectedine in patients with advanced localized myxoid liposarcoma. *Ann Oncol* 2012; 23(3): 771-776
119. **Gronchi A**, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG and Picci P. Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas (STS): a Randomized Clinical Trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS). *J Clin Oncol* 2012; 30(8): 350-356
120. Stacchiotti S, Longhi A, Ferraesi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, **Gronchi A**, Amore P, Vinaccia V and Casali PG. A Phase II study on imatinib in advanced chordoma. *J Clin Oncol* 2012; 30(9): 914-920
121. **Gronchi A** and Raut CP. The combination of Surgery and Imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. *Ann Surg Oncol* 2012; 19: 1051-1055
122. **Gronchi A**, Miceli R, Colombo C, Stacchiotti S, Collini P, Mariani L, Sangalli C, Radaelli S, Sanfilippo R, Fiore M and Casali PG. Frontline extended surgery is associated with improved survival in retroperitoneal low-intermediate grade soft tissue sarcomas. *Ann Oncol* 2012; 23(4):1067-1073
123. Siesling S, van der Zwan JM, Izarzugaza I, et al. Rare thoracic cancers, including peritoneum mesothelioma. *Eur J Cancer*. 2012; 48(7):949-960
124. Visser O, Trama A, Maynadié M, Stiller C, Marcos-Gragera R, De Angelis R, Mallone S, Tereanu C, Allemani C, Ricardi U, Schouten HC; RARECARE Working Group. Incidence, survival and prevalence of myeloid malignancies in Europe. *Eur J Cancer*. 2012; 48(17):3257-66
125. Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, **Gronchi A**, Corless CL, Goldstein D, Rubin B, Maki RB, Lazar AJ, Lev D, Trent JC and von Mehren M. Non-random association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): Case series of 28 patients. *Ann Oncol* 2012; 23(5): 1335-1340
126. Venturini L, Daidone MG, Motta R, Hoare SF, **Gronchi A**, Folini M, Keith WN, Zaffaroni N. Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. *Neuro-oncology* 2012;14(6):736-744.
127. Collini P, Negri T, Barisella M, Stacchiotti S, Palassini E, Tarantino E, Pastorino U, **Gronchi A**, Casali PG and Pilotti S High-Grade sarcomatous overgrowth in Solitary Fibrous Tumors: a clinical-pathological study of 10 cases. *Am J Surg Pathol* 2012; 36(8):1202-1215
128. Casali PG, Fumagalli E and **Gronchi A**. Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST). *Curr Treat Opt in Oncol* 2012; 13(3):277-284
129. Bonvalot S, Raut CP, Pollock RE, Rutkowski P, Strauss DC, Hayes AJ, Van Coevorden F, Fiore M, Stoeckle E, Hohenberger P and **Gronchi A**. Technical Considerations in Surgery For Retroperitoneal Sarcomas. Position paper from e-SURGE, a masterclass in sarcoma surgery, and EORTC - STBSG. *Ann Surg Oncol* 2012; 19(9):2981-2991
130. Colombo C, Ronellenfitch U, Yuxin Z, Rutkowski P, Miceli R, Bylina E, Hohenberger P, Raut CP and **Gronchi A**. Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study. *Ann Surg Oncol* 2012; 19(11):3361-3367
131. Reichardt P, Morosi C, Wardelmann E and **Gronchi A**. Gastrointestinal stromal tumors: Evolving role of the multidisciplinary team approach in management. *Expert Rev Anticancer Ther* 2012; 12(8):1053-1068
132. Colombo C, R Randall L, Andtbacka RHI and **Gronchi A**. A new surgical perspective in soft tissue sarcoma (STS) management: more conservative in ESTS (Extremity Soft Tissue Sarcoma), more extended in RSTS (Retroperitoneal Soft Tissue Sarcoma). *Expert Rev Anticancer Ther* 2012; 12(8):1079-1087
133. Colombo C, Miceli R, Collini P, Radaelli S, Palassini E, Stacchiotti S, Fiore M, Mariani L, Casali PG and **Gronchi A**. Leiomyosarcoma and sarcoma with myogenic differentiation: two different entities or two faces of the same disease? *Cancer* 2012; 118(21): 5349-5357



134. Stacchiotti S, Dagrada P, Morosi C, Negri T, Romanini A, Pilotti S, **Gronchi A** and Casali PG. Extraskeletal Myxoid Chondrosarcoma: tumor response to Sunitinib. *Clin Sarcoma Res* 2012; 2(1): 22
135. Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Llombart-Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Casali PG and **Gronchi A**. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy: an exploratory analysis on a Phase III trial. *Cancer* 2012; 118(23):5857-5866
136. Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, **Gronchi A**, Dei Tos AP, Morosi C, Messina A, Pilotti S, Casali PG. Sunitinib malate in solitary fibrous tumor (SFT). *Ann Oncol* 2012; 23(12):3171-3179
137. **Gronchi A** and Raut CP. Optimal approach to sporadic desmoid tumor: from radical surgery to observation. Time for a consensus ? *Ann Surg Oncol* 2012; 19:3995-3997
138. ESMO / European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7: vii92-99
139. ESMO / European Sarcoma Network Working Group. Gastrointestinal Stromal Tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7: vii49-55
140. ESMO / European Sarcoma Network Working Group. Bone Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7: vii100-109
141. Jakob J, Mussi C, Ronellenfisch U, Wardelmann E, Negri T, **Gronchi A** and Hohenberger P. Gastrointestinal Stromal Tumor (GIST) of the rectum: results of surgical and multimodality therapy in the era of Imatinib. *Ann Surg Oncol* 2013; 20(2):586-592.
142. **Gronchi A**. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with GIST. *Eur J Cancer* 2013; 49: 884-892
143. **Gronchi A**, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, Stacchiotti S, Ferrari S, Fiore M and Casali PG. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. *Ann Oncol* 2013; 24(3):817-23
144. **Gronchi A**, Miceli R, Shurell E, Eilber FC, Eilber FR, Anaya DA, Kattan MW, Honoré C, Lev DC, Colombo C, Bonvalot S, Mariani L and Pollock RE. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center datasets. *J Clin Oncol* 2013; 31:1649-1655
145. Stacchiotti S, Libertini M, Negri T, Palassini E, **Gronchi A**, Fatigoni S, Poletti P, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S and Casali PG. Response to chemotherapy of Solitary Fibrous Tumor: a retrospective study. *Eur J Cancer* 2013; 49(10): 2376-2383
146. **Gronchi A** and Pollock RE. Quality of local treatment or biology of the tumor: which are the trump cards for loco-regional control of retroperitoneal sarcoma? *Ann Surg Oncol* 2013; 20: 2111-2113.
147. Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, Casale A, Crippa F, Conca E, Negri T, Palassini E, Marrari A, Palmerini E, Mariani L, **Gronchi A**, Pilotti S, Casali PG. Phase II Study on Lapatinib in advanced EGFR positive Chordoma. *Ann Oncol* 2013; 24: 1931-1936
148. Rutkowski P and **Gronchi A**. Efficacy and economic value of adjuvant Imatinib in GIST. *The Oncologist* 2013; 18: 689-696.
149. Duranti L, **Gronchi A**, Stacchiotti S, Fiore M, Casali PG, Collini P, Pelosi G, Galeone C and Pastorino U. Localized thoracic sarcomas: outcome improvement over time at a single institution. *Eur J Cancer* 2013; 49: 2689-2697
150. Baldi G, Stacchiotti S, Mauro V, Dei Tos AP, **Gronchi A**, Pastorino U, Duranti L, Provenzano S, Marrari A, Libertini M, Pilotti S and Casali PG. Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. *Clin Sarcoma Res* 2013; 3(1): 4
151. Stacchiotti S, Crippa F, Messina A, Pilotti S, **Gronchi A**, Blay JY and Casali PG. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. *Clin Sarcoma Res* 2013; 3(1): 8
152. Mattavelli D, Miceli R, Radaelli S, Mattavelli F, Cantù G, Barisella M, Quattrone P, Stacchiotti S, Sangalli C, Casali PG, **Gronchi A** and Fiore M. Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. *Ann Oncol* 2013; 24(8): 2181-2189
153. Rutkowski P, **Gronchi A**, Hohenberger P, Bonvalot S, Schöffski P, Bauer S, Fumagalli E, Nyckowski P, Nguyen BP, Kerst JM, Fiore M, Bylina I, Hoiczky M, Cats A, Casali PG, Le Cesne A, Treckmann J, Stoeckle E, van de Wilt JH, Sleijfer S, Tielen R, van der Graaf W, Verhoef C and van Coevorden F. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST), the EORTC STBSG experience. *Ann Surg Oncol* 2013; 20(9): 2937-2943
154. **Gronchi A** and Casali PG. Adjuvant Therapy for High-Risk Soft Tissue Sarcoma in the Adult. *Curr Treat Opt in Oncol* 2013; 14(3):415-24
155. Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, Morosi C, Messina A, Libertini M, Palassini E, Cominetti D, Negri T, **Gronchi A**, Pilotti S, Zaffaroni N and Casali PG. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-à-vis temozolomide and antiangiogenics. *Clin Cancer Res* 2013; 19(18):5192-201
156. **Gronchi A**. Extended surgery for retroperitoneal sarcoma: the key to maximizing the potential for cure and survival. *Pro. Oncology (Williston Park)*. 2013; 27(7):640, 642



157. **Gronchi A** and Raut CP. Treatment of localized sarcomas. *Hematol Oncol Clin N Am* 2013; 27:921-938
158. Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le Cesne A, Hartgrink HH, Cleton-Jansen AM, Domont J, Bovée JVMG, Bonvalot S, Lev D, and **Gronchi A**. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent multicenter validation study. *Cancer* 2013; 119:3696-3702.
159. Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollé J, Sanfilippo R, **Gronchi A**, Perrone F, Tamborini E, Pelosi G, Pierotti M, Maestro R, Priol S and Pilotti S. In vitro and in silico studies of MDM2/MDMX isoforms predict NUTLIN-3A sensitivity in well/differentiated liposarcomas. *Lab Invest* 2013; 93(11): 1232-1240
160. Bonvalot S, Ternès N, Fiore M, Bitsakou G, Colombo C, Honoré C, Marrari A, Le Cesne A, Perrone F, Dunant A and **Gronchi A**. Spontaneous regression of primary abdominal wall desmoids: more common than previously thought. *Ann Surg Oncol* 2013; 20(13): 4096-4102
161. Raut CP and **Gronchi A**. Cytoreductive Surgery in Advanced GIST: timing is everything. *Ann Surg Oncol* 2013; 20(13): 4059-4060
162. Stacchiotti S, Dagrada G, Sanfilippo R, Negri T, Vittimberga I, Ferrari S, Grosso F, Apice G, Tricomi M, Colombo C, **Gronchi A**, Dei Tos AP, Pilotti S and Casali PG. Anthracycline-based CT in extraskeletal myxoid chondrosarcoma: a retrospective study. *Clinical Sarcoma Research* 2013; 3: 16.
163. Mallone S, De Angelis R, van der Zwan JM, Trama A, Siesling S, Gatta G, Capocaccia; RARE CARE WG. Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project. *Cancer Epidemiol* 2013; 37(6): 850-856
164. Martin-Broto J, Gutierrez AM, Ramos RF, Lopez-Guerrero JA, Ferrari S, Stacchiotti S, Picci P, Calabuig S, Collini P, Gambarotti M, Bague S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martinez-Trufero J, Poveda A, Casali PG, Fernandez A, Lopez-Pousa A and **Gronchi A**. MRP1 overexpression determines poor prognosis in prospectively treated localized high risk soft tissue sarcoma patients of limbs and trunk wall. An ISG/GEIS study. *Mol Cancer Ther* 2014, 13(1):249-59
165. Bozzi F, Manenti G, Conca E, Stacchiotti S, Messina A, Dagrada G, **Gronchi A**, Panizza P, Pierotti M, Tamborini E and Pilotti S. Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. *Neuro-Oncol* 2014; 16(1):72-80
166. **Gronchi A**, De Paoli A, Dani C, Merlo DF, Quagliuolo V, Grignani G, Bertola G, Navarra P, Sangalli C, Buonadonna A, De Sanctis R, Sanfilippo R, Dei Tos AP, Stacchiotti S, Giorello L, Fiore M, Bruzzi P and Casali PG. Preoperative chemo-radiation therapy for localized retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. *Eur J Cancer* 2014; 50:784-792
167. **Gronchi A**, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M and Bonvalot S on behalf of ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm. A position paper from the Italian and the French Sarcoma Group. *Ann Oncol* 2014; 25(3): 578-583
168. Meazza C, Luksch R, Daolio P, Podda M, Luzzati A, **Gronchi A**, Parafioriti A, Gandola L, Collini P, Ferrari A, Casanova M, Terenziani M, Spreafico F, Polastri D, Biassoni V, Schiavello E, Pecori E, Massimino M. Axial Skeletal Osteosarcoma: a 25 year monoinstitutional experience in children and adolescence. *Med Onc* 2014; 31(4): 875
169. Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczky M, Cats A, Casali PG, Treckmann J, van Coevorden F, **Gronchi A**. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - analysis of prognostic factors (EORTC-STBSG collaborative study). *Eur J Surg Oncol* 2014; 40(4):412-419
170. Pastorino U, Duranti L, Scannagatta P, Leo F, Piccioni F, Collini P and **Gronchi A**. Thoracopleuropneumectomy with rib-like reconstruction for recurrent thoracic sarcomas. *Ann Surg Oncol* 2014; 21(5):1610-1615
171. Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, Le Cesne A, Gladdy RA, Casali PG, Swallow CJ, **Gronchi A**, Bonvalot S and Raut RP. Desmoid-type Fibromatosis and pregnancy. A multi-institutional analysis of recurrence and obstetric risk. *Ann Surg* 2014; 259(5):973-978.
172. Radaelli S, Stacchiotti S, Casali PG and **Gronchi A**. Emerging Therapies for Adult Soft Tissue Sarcomas. *Exp Rev Anticancer Ther* 2014; 14(6):689-704
173. Stacchiotti S, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, **Gronchi A**, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestri R, Pilotti S and Casali PG. Activity of Sunitinib in Extraskeletal Myxoid Chondrosarcoma. *Eur J Cancer* 2014; 50(9): 1657-1664
174. **Gronchi A**, Colombo C and Raut CP. Surgical Management of Localized Soft Tissue Tumors. *Cancer* 2014; 120(17):2638-2648
175. De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada GP, Disciglio V, Sanfilippo R, **Gronchi A**, D'Incalci M, Casali PG, Canevari S, Pierotti MA, Pilotti S. Identification of a gene expression driven progression pathway in Myxoid Liposarcoma. *Oncotarget* 2014; 5(15):5965-5977
176. Radaelli S, Desai A, Hodson J, Colombo C, Roberts K, Gourevitch D and **Gronchi A**. Prognostic factors and outcome of Spermatic Cord Sarcoma. *Ann Surg Oncol* 2014; 21:3557-3563
177. ESMO / European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2014; 25 (Supplement 3): iii102–iii112.



178. ESMO / European Sarcoma Network Working Group. Gastrointestinal Stromal Tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2014; 25 (Supplement 3): iii21–iii26.
179. ESMO / European Sarcoma Network Working Group. Bone Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2014; 25 (Supplement 3): iii113–iii123.
180. Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, Casali PG, Grosso F, Sanfilippo R, **Gronchi A**, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JMF and D'Incalci M. Mode of action of trabectedin in myxoid liposarcoma. *Oncogene* 2014; 33(44):5201-5210
181. Tazzari M, Negri T, Rini F, Vergani B, Huber V, Villa A, Dagrada P, Colombo C, Fiore M, **Gronchi A**, Stacchiotti S, Casali PG, Pilotti S, Rivoltini L and Castelli C. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. *Br J Cancer* 2014; 11(7):1350-1362
182. van Broekhoven DLM, Deroose JP, Bonvalot S, **Gronchi A**, Grünhagen DJ, Eggermont AMM and Verhoef C. Isolated limb perfusion by tumor necrosis factor alpha and melphalan in patients with advanced aggressive fibromatosis. *Br J Surg* 2014; 101(13):1674-80.
183. Le Cesne A, Ouali M, Leahy MG, Santoro, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, **Gronchi A**, Hogendoorn PCW, Litiere S, Marreud S, Blay JY and Van Der Graaf WTA. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. *Ann Oncol* 2014; 25(12):2425-2432
184. Sanfilippo R, Bertulli R, Marrari A, Fumagalli E, Pilotti S, Morosi C, Messina A, Dei Tos AP, **Gronchi A** and Casali PG. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. *Clin Sarcoma Res* 2014; 4:16
185. Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, **Gronchi A**, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG and Zaffaroni N. Preclinical and clinical evidence of activity of Pazopanib in Solitary Fibrous Tumor. *Eur J Cancer* 2014; 50(17):3021-8
186. Morosi C, Stacchiotti S, Marchianò A, Bianchi A, Radaelli S, Sanfilippo R, Colombo C, Richardson C, Collini P, Barisella M, Casali PG, **Gronchi A**, Fiore M. Correlation between Radiological Assessment and Histopathological Diagnosis in Retroperitoneal Tumors: analysis of 291 consecutive patients at a tertiary referral Sarcoma Center. *Eur J Surg Oncol* 2014; 40(12):1662-1670
187. Stiller CA, Trama A, Brwster DH, Verne J, Bouchardy C, Navarro C, Chirlaque MD, Marcos-Gragera R, Visser O, Serraino D, Weiderpass E, Dei Tos AP, Ascoli V; Rarecare Working Group. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. *Cancer Epidemiol* 2014; 38(6):670-678
188. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult. A Consensus Approach from the Trans-Atlantic RPS Working group\* *Ann Surg Oncol* 2015; 22(1): 256-263
189. Kasper B, Baumgarten C, Bonvalot S, Haas R, Haller F, Hohenberger P, Moreau G, Van der Graaf W and **Gronchi A**. Management of Sporadic Desmoid-Type Fibromatosis: A European consensus approach based on patients' and professionals' expertise - A Sarcoma Patients EURONET (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC) / Soft Tissue and Bone Sarcoma Group (STBSG) initiative. *Eur J Cancer* 2015; 51(2):127-136
190. Casali PG, Bruzzi P, Bogaerts J and Blay JY on behalf of the Rare Cancers Europe (RCE) Consensus Panel. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. *Ann Oncol* 2015; 26(2):300-306
191. Colombo C, Miceli R, Le Péchoux C, Palassini E., Honoré C, Stacchiotti S, Mir O , Casali PG, Dômont J, Fiore M, Le Cesne A, **Gronchi A** and Bonvalot S. Sporadic Extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. *Eur J Cancer* 2015; 51(2):186-192
192. Palmerini E, Staals EL, Maki RG, Pengo S, Cioffi A, Gambarotti A, Picci P, Daolio PA, Parafioriti A, Morris C, Antonescu CR, **Gronchi A**, Casali PG, Donati DM, Ferrari S, Stacchiotti S. Tenosynovial giant cell tumor/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. *Eur J Cancer* 2015; 51(2):210-217
193. **Gronchi A**. Individualizing the use/non-use of radiation therapy (RT) in soft tissue sarcoma (STS): when abstention is better than care. *J Surg Oncol* 2015; 111(2):133-134
194. **Gronchi A**, Collini P, Miceli R, Renne SL, Dagrada G, Fiore M, Sanfilippo R, Barisella M, Colombo C, Morosi C, Stacchiotti S, Casali PG, Dei Tos AP and Pilotti S. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma. *Am J Surg Pathol* 2015; 39(3):383-93
195. Stacchiotti S, Sommer J, Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. *Lancet Oncol* 2015;16(2): e71-83
196. Colombo C, Baratti D, Kusamura S, Deraco M and **Gronchi A**. The role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Isolated Perfusion (ILP) Interventions in Sarcoma. *J Surg Oncol* 2015; 111(5):570-579
197. Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, Casanova J, Esler C, Ferrari S, Funovics PT, Gerrand C, Grimer R, **Gronchi A**, Haffner N, Hecker-Nolting S, Höller S, Jeys L, Jutte P, Leithner A, San-Julian M, Thorkildsen J, Vincenzi B, Windhager R, Whelan J. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study.. *Eur J Cancer* 2015; 51(3):374-81.



198. **Gronchi A**, Miceli R, Allard MA, Callegaro D, Le Pécoux C, Fiore M, Honoré C, Sanfilippo R, Coppola S, Stacchiotti S, Terrier P, Casali PG, Le Cesne A, Mariani L, Colombo C and Bonvalot S. Personalizing the approach to Retroperitoneal Soft Tissue Sarcoma: histology specific patterns of failure and post-relapse outcome after primary extended resection. *Ann Surg Oncol* 2015; 22(5):1447-54
199. Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litiere S, Bonnetain F, Dabakuyo TS, Benjamin R, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grossclaude P, **Gronchi A**, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Karup-Hansen A, Le Pécoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut CP, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gorgou-Bourgade S, Mathoulin-Pelissier S. Guidelines for time-to-event endpoint definitions in sarcoma and gastrointestinal stromal tumor (GIST) trials. Results of the DATECAN initiative (Definition for the Assessment of Time-to event Endpoints in CANcer trials). *Ann Oncol* 2015; 26:865–872
200. Callegaro D, Fiore M and **Gronchi A**. Personalizing surgical margins in retroperitoneal sarcoma. *Exp Rev Anticancer Ther* 2015; 15(5):553-67
201. Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, Marzotto A, Boscato E, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Mariani L, Amore P, **Gronchi A**, Casali PG, Maestro R, and Dei Tos AP. KIT, PDGFRA and BRAF mutational spectrum impacts on the natural history of Imatinib-naïve localized GIST: a population-based study. *Am J Surg Pathol* 2015; 39(7):922-930
202. Callegaro D, Miceli R, Brunelli C, Colombo C, Sanfilippo R, Radaelli S, Casali PG, Caraceni A, **Gronchi A**, Fiore M. Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. *Br J Surg* 2015; 102:1079-1087
203. Dagrada GP, Spagnuolo RD, Mauro V, Tamborini E, Cesana L, **Gronchi A**, Stacchiotti S, Pierotti MA, Negri T and Pilotti S. Solitary Fibrous Tumor: loss of chimeric protein expression and genomic instability mark dedifferentiation. *Mod Pathol* 2015; 28(8):1074-1083
204. Hohenberger P, Gorlick R, **Gronchi A**. Collaborations Between SSO and the Connective Tissue Oncology Society (CTOS) Series. *Ann Surg Oncol* 2015; 22(9): 2815-2816
205. Palassini E, Ferrari S, Verderio P, De Paoli A, Martin Broto J, Quagliuolo V, Comandone A, Sangalli C, Palmerini E, Lopez-Pousa A, De Sanctis R, Bottelli S, Libertini M, Picci P, Casali PG and **Gronchi A**. Feasibility of pre-operative chemotherapy + radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk within the ISG/GEIS randomized clinical trial on 3 vs 5 cycles of full-dose epirubicin + ifosfamide. *J Clin Oncol* 2015; 33(31):3628-3634
206. Hindi N, Casali PG, Morosi C, Messina A, Palassini E, Pilotti S, Tamborini E, Radaelli S, **Gronchi A**, Stacchiotti S. Imatinib in advanced chordoma: a retrospective case series analysis. *Eur J Cancer* 2015; 51:2609-14
207. Fiore M, Colombo C, Radaelli S, Callegaro D, Palassini E, Barisella M, Morosi C, Baldi GG, Stacchiotti S, Casali PG, **Gronchi A**. Hormonal manipulation with Toremifene in Sporadic Desmoid-type Fibromatosis. *Eur J Cancer* 2015; 51:2800-2807
208. Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann J, Goldstein D, Martin Broto J, **Gronchi A**, Dei Tos AP, Matreud S, van der Graaf W, Zalcberg JR, Litiere S and Blay JY. Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with Imatinib as an adjuvant: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS). *J Clin Oncol* 2015; 33:4276-4283
209. Wardelmann E, Haas RL, Bovée JVMG, Terrier Ph, Lazar A, Messiou C, LePécoux C, Hartmann W, Collin F, Fisher C, Mechttersheimer G, Dei Tos AP, Stacchiotti S, Jones R, **Gronchi A**, Bonvalot S. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. *Eur J Cancer* 2016; 53:84-95
210. Messiou C, Bonvalot S, **Gronchi A**, Vanel D, Meyer M, Robinson P, Morosi C, Bloem JL, Terrier PH, Lazar A, LePécoux C, Wardelman E, Winfield JM, Boulet B, Haas RL. Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on Magnetic Resonance Imaging. *Eur J Cancer* 2016; 56: 37-44
211. Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, **Gronchi A**, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, Casali PG. Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP). *Clin Cancer Res* 2016; 22(4):837-46
212. Venterie M, Litière S, Rizzo E, Marréaud S, Judson I, Gelderblom I, Le Cesne A, Wardelmann E, Messiou C, **Gronchi A**, van der Graaf WTA. Outcome of chemotherapy in advanced synovial sarcoma patients: review of 15 clinical trials from European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG); Setting a new landmark for studies in this subtype. *Eur J Cancer* 2016; 58: 62-72
213. **Gronchi A**, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE and Raut CP. Variability in patterns of recurrence after resection of Primary Retroperitoneal Sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative Transatlantic RPS Working Group. *Ann Surg* 2016; 263(5):1002-1009



214. Raut CP, Miceli R, Strauss DC, Swallow CJ, Hohenberger P, van Coevorden F, Rutkowski P, Fiore M, Callegaro D, Casali PG, Haas RL, Hayes AJ, Honoré C, Cannell AJ, Jakob J, Szacht M, Fairweather M, Pollock RE, Bonvalot S, **Gronchi A**. External Validation of a Multi-Institutional Retroperitoneal Sarcoma Nomogram. *Cancer* 2016; 122(9):1417-24
215. Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Lorusso D, Sabatucci I, Carcangiu ML, Fiore M, **Gronchi A**, Raspagliesi F. Morcellator's port-site metastasis of a uterine smooth muscle tumor of uncertain potential after minimally invasive myomectomy. *J Minim Invasive Gynecol.* 2016; 23(4):647-9.
216. Saponara M, Stacchiotti S and **Gronchi A**. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. *Exp Rev Anticancer Ther* 2016; 16(5):473-484
217. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Le Pechoux C, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Mariani L, Wunder JS, Pollock RE, Casali PG and **Gronchi A**. Development and external validation of two nomograms to predict overall survival and distant metastases after surgical resection of localised soft tissue sarcomas of the extremities: a retrospective analysis. *Lancet Oncol* 2016; 17:671-680
218. Radaelli S, Fiore M, Colombo C, Ford S, Palassini E, Sanfilippo R, Stacchiotti S, Sangalli C, Morosi C, Casali PG and **Gronchi A**. Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. *Surg Oncol* 2016; 25(3): 125-131
219. **Gronchi A**, Guadagnolo BA, Erinjeri JP. Local Ablative Therapies to Metastatic Soft Tissue Sarcoma. *Am Soc Clin Oncol Educ Book.* 2016;35:e566-e575
220. Radaelli S, Stacchiotti S, Ruggieri P, Donati D, Casali PG, Palmerini E, Collini P, Gambarotti M, Porcu L, Boriani S, **Gronchi A**, Picci P. Sacral Chordoma: Long-Term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers. *Spine* 2016; 41(12):1049-1057.
221. Ford S and **Gronchi A**. Indications for Surgery in Advanced/Metastatic GIST. *Eur J Cancer* 2016; 63: 154-167
222. Grünwald V, Young R, Messiou C, Lia M, Wardelmann E, van der Graaf W, **Gronchi A**, Judson I for the EORTC STBSG. Absence of progression, not extent of remission tumour shrinkage defines prognosis in soft tissue sarcoma – an analysis of the EORTC 62012 study of the EORTC STBSG. *Eur J Cancer* 2016; 64:44-51.
223. Ray-Coquard I, Litiere S, Rizzo E, Blay JY, Casali PG, Judson I, Krarup Hansen A, Lindner LH, Dei Tos AP, Gelderblom H, Marreard S, Rutkowski P, Hohenberger P, **Gronchi A**, Van der Graaf WT. Impact of chemotherapy in Uterine Sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other Soft Tissue Sarcoma (STS) patients treated with first line chemotherapy. *Gynecol Oncol* 2016;142(1):95-101
224. **Gronchi A**, Haas RL and Bonvalot S. Cancer Registries and randomized clinical trials in rare tumors: at the 2 extremes of daily clinical practice. *Eur J Cancer* 2016; 64:113-115
225. Meazza C, Perrone F, Belfiore A, Busico A, Settanni G, Paielli N, Cesana L, Ferrari A, Chiaravalli S, **Gronchi A**, Colombo C, Pilotti S, Massimino A. AKT1 and BRAF mutations in pediatric aggressive fibromatosis. *Cancer Med* 2016; 5(6):1204-13
226. Pasquali S, **Gronchi A**, Strauss D, Bonvalot S, Jeys L, Stacchiotti S, Hayes A, Honoré C, Collini P, Renne SL, Alexander N, Grimer RJ, Callegaro D, Sumathi VP, Gourevitch D, Desai A. Resectable extrapleural and extrameningeal Solitary Fibrous Tumor: a multi centre prognostic study. *Eur J Surg Oncol* 2016; 42:1064-1070
227. Eastley N, McCulloch T, Esler C, Hennig I, Fairbairn J, **Gronchi A** and Ashford R. Extra-abdominal Desmoids Fibromatosis: a review of management, current guidance and unanswered questions. *Eur J Surg Oncol* 2016; 42:1071-1083
228. Stacchiotti A, Provenzano S, Dagrada GP, Negri T, Brich S, Basso U, Brunelio A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, **Gronchi A**, Dei Tos AP, Crippa F, Morosi C, Pilotti S and Casali PG. Sirolimus in advanced hemangioendothelioma: a retrospective case series analysis from the Italian Rare Cancer Network database. *Ann Surg Oncol* 2016; 23(9):2735-44
229. van Broekhoven DL, Grünhagen DJ, van Dalen T, van Coevorden F, Bonenkamp HJ, Been LB, Bemelmans MH, Dijkstra SD, Colombo C, **Gronchi A**, Verhoef C. Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention. *BMC Cancer.* 2016;16(1):686
230. Fiore M, MacNeill A, **Gronchi A**, Colombo C. Desmoid-type Fibromatosis: evolving treatment standards. *Surg Oncol Clin N Am* 2016; 25:803-826
231. Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult. A Consensus Approach from the Trans-Atlantic RPS Working group\*. *Ann Surg Oncol* 2016; 23:3531-3540
232. Stacchiotti S, Astolfi A, **Gronchi A**, Fontana A, Pantaleo MA, Negri T, Brenca M, Tazzari M, Urbini M, Indio V, Colombo C, Radaelli S, Brich S, Dei Tos AP, Casali PG, Castelli C, Dagrada GP, Pilotti S, Maestro R. Evolution of Dermatofibrosarcoma protuberans (DFSP) to DFSP-derived fibrosarcoma (FS-DFSP): an event marked by epithelial mesenchymal transition-like process and 22q loss. *Mol Cancer Res* 2016; 14(9):820-9
233. **Gronchi A**, Delrio P, Quagliuolo V, Sandrucci S. The Italian Society of Surgical Oncology (SICO) survey on the minimum requirements of rare cancers referral centers. *Updates Surg in press*



234. Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, Stacchiotti S, Dagrada GP, Casali PG, **Gronchi A**, Astolfi A, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C. Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment. *J Invest Dermatol* in press
235. Gasparotto D, Rossi S, Polano M, Tamborini E, Lorenzetto E, Sbaraglia M, Mondello A, Massani M, Lamon S, Bracci R, Mandolesi A, Frate E, Stanzial F, Agaj J, Mazzoleni G, **Gronchi A**, Dei Tos AP and Maestro R. Quadruple-negative GIST is a sentinel for unrecognized Neurofibromatosis Type 1 syndrome. *Clin Cancer Res* in press
236. Sandrucci S, Trama A, Quagliuolo V, **Gronchi A**. Accreditation for centers of sarcoma surgery. *Updates Surg* in press
237. **Gronchi A**, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch S, Dei Tos AP, Collini P, Cruz Jurado J, De Paoli A, Donati DM, Poveda A, Quagliuolo A, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, Casali PG and Picci P. Short, Full-Dose Adjuvant Chemotherapy (CT) in High-Risk Adult Soft Tissue Sarcomas (STS): Long term Follow-Up of a Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. *Ann Oncol* in press
238. Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Boccone P, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf W, Touati N, Litière S, Marreaud S, **Gronchi A**, Kasper B. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. *Acta Oncol* in press
239. Tseng WW, Pollock RE and **Gronchi A**. The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG): "Red wine or white"? *Ann Surg Oncol* in press
240. Saponara M, Stacchiotti S, Casali PG and **Gronchi A**. (Neo)adjuvant treatment in localized soft tissue sarcoma (STS): the unsolved affair. *Eur J Cancer* in press



## 1. Allegato 2

### Elenco delle pubblicazioni non censite da Medline, in inglese

1. **Gronchi A**, Casali PG, Olmi P. Sacro-coccygeal chordoma: diagnosis and treatment review. Sem Col Rectal Surg, 2004; 15(1): 26-32.
2. **Gronchi A**, Casali PG The impact of systemic treatment on patient survival of soft tissue sarcoma. Eur Oncol in press
3. Thomas DM, **Gronchi A**, O'Sullivan B. A multidisciplinary approach to retroperitoneal sarcoma. Am Soc Clin Oncol Ed Book 1701-1708, 2009
4. Pennacchioli E, Colombo C, Berselli M and **Gronchi A**. Update on management of GIST and postsurgical use of imatinib. Open Access Surgery 2010; 3: 63-71.
5. Radaelli S, Desai A, Colombo C, Fiore M and **Gronchi A**. Perioperative therapies for localized retroperitoneal soft tissue sarcoma. Oncology and Hematology Review 2012; 8(1): 65-70



### Allegato 3

#### Elenco dei **Capitoli di libri**, in inglese

- **Gronchi A** and Fiore M. Chordoma. In Khatri VP ed: Clinical Scenarios in Surgical Oncology. Philadelphia: Lippincott Williams & Wilkins; 2006: 299-302.
- Santinami M, **Gronchi A**, Maurichi M, Zoras O, Patuzzo R, Pennacchioli E. Limb's perfusion: rationale, techniques and results. In Zoras O ed: Regional Oncotherapies. Athens: Paschalidis Medical Publications Ltd; 2006:193-226.
- **Gronchi A**, Colombo C and Fiore M. Surgery of Primary Tumor. In Blay JY ed: 100 Key Questions on Soft Tissue Sarcoma. Mallorca: Permanyer Publications; 2010: 55-67.
- **Gronchi A**, Fiore M, Palaia R. Surgical Treatment. In de Lutio di Castelguidone E and Messina A eds: GISTs - Gastrointestinal Stromal Tumors. Milan: Springer Verlag Italia; 2011: 107-112.
- Fletcher CDM, Singer S, **Gronchi A**. Tumor of Soft Tissue: Introduction. In Fletcher CDM, Bridge JA, Hogendoorn PCW and Mertens F eds: WHO Classification of Tumours of Soft Tissue and Bone. Lyon; IARC; 2013: 14-16
- **Gronchi A**. Surgical Management of Soft Tissue Sarcomas. In Blay JY ed. Atlas of data and images on STS. Madrid; Grupo Editorial Entheos. 2013: 177-231
- Raut CP and **Gronchi A**. The management of Soft Tissue Sarcoma. In Cameron JL and Cameron AM eds: Current Surgical Therapy. Philadelphia: Elsevier Saunders; 2014: 706-717
- Comier JN, **Gronchi A** and Pollock RE. Soft Tissue Sarcoma. In Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, Pollock RE eds: Schwartz's Principles of Surgery. New York: McGraw-Hill Professional; 2014: 1465-1493
- Casali PG, Dei Tos AP and **Gronchi A**. Gastrointestinal Stromal Tumor. In DeVita, Hellman, and Rosenberg eds: Cancer. Principles & Practice of Oncology. Philadelphia Wolters Kluwer Health; 2015: 745-756
- **Gronchi A**, Dei Tos AP, Casali PG. Sarcomas of Soft Tissue and Bone. In Kerr DJ, Haller DG, van de Velde CJH, Baumann M eds: Oxford Textbook of Oncology. Oxford: Oxford University Press; 2016: 844-866
- Fontana A, Callegaro D and **Gronchi A**. Standard of care in early phases. In Blay JY ed: 100 Key Questions on Soft Tissue Sarcoma. Mallorca: Permanyer Publications; 2016: 17-28



## Allegato 4

### Elenco dei Libri, in italiano

- Azzarelli A, **Gronchi A**, De Pas T, Marsiglia HR. Strategia terapeutica integrata in Sarcomi delle parti molli. In Veronesi U ed. Oncologia Chirurgica. Milano: Masson; 1999: 869-875.
- Casali PG, **Gronchi A**, Olmi P, Rosai J. Basi scientifiche per la definizione di linee guida in ambito clinico per i sarcomi dei tessuti molli dell'adulto. In Silvestrini R ed. Progetto Strategico Oncologia. Milano: CNR-MIUR; 2002.
- Casali PG, **Gronchi A**, Olmi P e Azzarelli A. Sarcomi delle parti molli dell'adulto. In Bonadonna G, Robustelli della Cuna G, Valagussa P, eds Medicina Oncologica. Milano: Masson; 2003: 1261-1274.
- Mussi C and **Gronchi A**. Tumori primitivi della parete addominale. In Croce, Olmi eds Chirurgia della parete addominale. Milano: Masson; 2006: 299-305.
- Mussi C and **Gronchi A**. Tumore desmoide. In Croce, Olmi eds Chirurgia della parete addominale. Milano: Masson; 2006: 307-310.
- **Gronchi A**, Colombo C and Fiore M. Il ruolo della chirurgia. In A. Comandone e S. Barni eds. I sarcomi dei Tessuti Molli. Roma: Il Pensiero Scientifico Editore; 2011: 103-123.
- Casali PG, Comandone A, Ferrari S, **Gronchi A**, Dei Tos AP. Sarcomi. In Cascinu S, Labianca R eds. La medicina Oncologica. Diagnosi, terapia e gestione clinica. Roma: Edra; 2013:



## Annex 5

### Elenco dei Trial Clinici condotti

- Localized High-Risk Soft Tissue Sarcomas of the Extremities and Superficial Trunk in Adults: an Integrated Approach Comprising 3 or 5 Cycles of Adjuvant Chemotherapy. A prospective controlled randomized trial from Italians Sarcoma Group and Spanish Sarcoma Group. **Principal Investigator**. Study accrual closed in 2007 (328 patients recruited). Reported at ASCO as oral presentation in 2010. Published in J Clin Oncol in 2012
- A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (YONDELIS®) in Patients with Localized Myxoid / Round Cell Liposarcoma. **Principal Investigator**. Study accrual closed in 2009 (30 patients recruited); reported at ESMO as oral presentation in 2009 and at ASCO as poster discussion in 2009. Published in Ann Oncol in 2012.
- Preoperative Chemo-Radiation Therapy in Retroperitoneal Soft Tissue Sarcomas ( $\pm$  Radiation Boost). A multicentric phase II study from Italian Sarcoma Group. **Principal Investigator**. Study accrual closed in 2010 (86 patients recruited). Preliminary results reported at ASCO as poster discussion and at CTOS as oral presentation in 2011. Final results reported at ASCO in 2013 as poster discussion. Published in Eur J Cancer in 2014.
- A Phase III Randomized Study Evaluating Surgery of Residual Disease in Patients with Metastatic Gastro-Intestinal Stromal Tumor Responding to Imatinib Mesylate. A EORTC study (62063). **Principal Investigator**. Closed in advance for poor accrual in 2011 (12 patients recruited)
- Localized High-Risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults: an Integrating Approach Comprising Standard vs Histotype-Tailored Neoadjuvant Chemotherapy. **Principal Investigator**. Accrual started in 2011.
- A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma. A EORTC study (62092-22092). **Coinvestigator**. Accrual started in 2012
- Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoids tumor patients: an observational study. **Principal Investigator**. Accrual started in 2013
- Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus Radiotherapy in Soft Tissue Sarcoma patients (TRASTS). **Principal Investigator**. Accrual started in 2015
- NBTXR3-301 - A multicenter randomized, open-label phase II/III study, to compare the efficacy of NBTXR3, implanted as intratumor injection and activated by radiotherapy, versus radiotherapy alone in patients with locally advanced soft tissue sarcoma of the extremity and trunk wall. **Coinvestigator**. Accrual started in 2016

Mile 18/10/2016

